We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
ASH Recaps "Phenomenal" Year for Acute Myeloid Leukemia Drug Approvals.
- Authors
Doyle, Chase
- Abstract
Information about the ASH 2017 conference on the drug approvals for the treatment of patients with acute myeloid leukemia (AML) and their safety and efficacy issues is presented. It highlights the major drug approvals such as Rydapt, Vyxeos, Mylotarg and Idhifa for AML patients. It states that the recent approval includes a lower recommended dose, a different schedule in combination with chemotherapy.
- Subjects
DRUG approval; ACUTE myeloid leukemia treatment; ACUTE myeloid leukemia; CANCER chemotherapy; DRUG efficacy; CONFERENCES &; conventions; PATIENTS
- Publication
Oncology Practice Management, 2018, Vol 8, Issue 2, p31
- ISSN
2164-4403
- Publication type
Proceeding